Welcome to our dedicated page for Purple Biotech SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Purple Biotech Ltd. SEC filings document foreign private issuer current reports for a clinical-stage oncology biotechnology company and its PPBT American depositary shares. Recent Form 6-K filings attach press releases and corporate presentations covering CAPTN-3, IM1240 and IM1305, preclinical and toxicology data, oncology development plans, collaboration announcements, scientific advisory activity, operating results, and risk-related forward-looking disclosures.
The filing record also reflects capital-structure and market-status matters, including ADS ratio disclosures and Nasdaq minimum bid price compliance. The company’s 6-K reports are incorporated by reference into registration statements on Form F-3 and Form S-8, linking current reports to shelf registration and equity-plan disclosure frameworks.
Purple Biotech Ltd. submitted a Form 6-K as a foreign private issuer to furnish an updated corporate presentation titled “Purple Biotech Corporate Presentation January 2026.” This presentation is included as Exhibit 99.1 and is intended to provide current information about the company in January 2026.
The report is formally authorized on behalf of Purple Biotech Ltd. and is signed by Chief Executive Officer Gil Efron, dated January 12, 2026.
Purple Biotech Ltd. reported a key preclinical milestone for IM1240, a tri-specific antibody from its CAPTN-3 platform, in a non-human primate toxicology study. IM1240’s proprietary CD3 capping design enabled dosing up to 300-fold higher than a non-capped comparator, with markedly reduced immune-related toxicity and minimal cytokine release, suggesting a wider safety margin than certain current T cell engagers. The study also showed a favorable pharmacokinetic profile, with increased systemic exposure and a prolonged circulating half-life linked to its human serum albumin moiety and capping design. Purple Biotech plans to advance IM1240 toward first-in-human clinical trials, with a regulatory submission targeted for the second half of 2026, while continuing to develop its broader oncology pipeline, including CAPTN-3 candidates IM1240 and IM1305, and clinical-stage assets CM24 and NT219.
Purple Biotech Ltd. reports that shareholders approved all proposals presented at its Extraordinary General Meeting held on December 15, 2025 at the company offices in Rehovot, Israel. The proposals were described in the company proxy statement furnished on October 28, 2025 and received the requisite votes under Israeli Companies Law and the company articles of association.
The company also states that this Form 6-K, including its exhibits, is incorporated by reference into multiple existing registration statements on Forms S-8 and F-3, so those offering documents now include these meeting results.
Purple Biotech Ltd. filed a Form 6-K to notify investors that it has released an updated corporate presentation titled “Purple Biotech Corporate Presentation November 2025.” The presentation is furnished as Exhibit 99.1. This type of filing is mainly informational, giving the market updated background on the company and its activities rather than announcing a specific transaction or new financial results.
Purple Biotech Ltd. furnished a Form 6-K announcing that, on November 14, 2025, it issued a press release titled “Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update,” attached as Exhibit 99.1.
The Form 6-K, including all exhibits, is incorporated by reference into the company’s existing Form F-3 and Form S-8 registration statements, making it part of those filings from the date of submission, to the extent not superseded by later reports.
Purple Biotech Ltd. furnished a Form 6-K noting it issued a press release titled “Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform.” The press release is included as Exhibit 99.1 and is dated October 29, 2025.
The filing is administrative and points readers to the attached press release for details on the IM1240 manufacturing milestone from the CAPTN-3 platform.
Purple Biotech Ltd. (PPBT) announced an Extraordinary General Meeting of Shareholders to be held on December 15, 2025 at 4:30 p.m. Israel time at its executive offices, 4 Oppenheimer Street, Science Park, Rehovot, Israel.
The company furnished a Notice and Proxy Statement (with a Voting Slip for ordinary shareholders) as Exhibit 99.1. BNY Mellon, the ADS depositary, will distribute a Voting Instruction Form to ADS holders (attached as Exhibit 99.2). The materials are incorporated by reference into existing Form S-8 and Form F-3 registration statements.
Purple Biotech Ltd. (PPBT) furnished a Form 6-K reporting that on October 20, 2025 it issued a press release titled “Purple Biotech Announces Receipt of Nasdaq Regarding Minimum Bid Price Notification.”
The press release is included as Exhibit 99.1. This filing serves as a notice to investors about the company’s receipt of a Nasdaq minimum bid price notification and provides the related disclosure via the attached exhibit.
Purple Biotech Ltd. entered into a new at-the-market equity offering agreement with H.C. Wainwright & Co., LLC, allowing it to sell American Depositary Shares (ADSs), each representing 200 ordinary shares, from time to time through Wainwright as agent. These sales will be made under an existing Form F-3 shelf registration statement, with a prospectus supplement that permits ADS sales of up to an aggregate offering price of $2,300,000.
The company also terminated its prior at-the-market program with Jefferies LLC, which had been in place since 2021. Under the Jefferies program, Purple Biotech sold 983,317 ADSs for aggregate gross proceeds of $7,729,691, at an average price of $7.86 per ADS. The 6-K and its exhibits are incorporated by reference into multiple existing registration statements.
Purple Biotech Ltd. entered into a new at-the-market equity offering agreement with H.C. Wainwright & Co., LLC, allowing it to sell American Depositary Shares (ADSs), each representing 200 ordinary shares, from time to time through Wainwright as agent. These sales will be made under an existing Form F-3 shelf registration statement, with a prospectus supplement that permits ADS sales of up to an aggregate offering price of $2,300,000.
The company also terminated its prior at-the-market program with Jefferies LLC, which had been in place since 2021. Under the Jefferies program, Purple Biotech sold 983,317 ADSs for aggregate gross proceeds of $7,729,691, at an average price of $7.86 per ADS. The 6-K and its exhibits are incorporated by reference into multiple existing registration statements.
Purple Biotech Ltd. (PPBT) is a clinical-stage pharmaceutical company focused on oncology candidates including NT219, CM24 and IM1240. The prospectus supplement outlines ongoing and planned clinical programs, collaborations, capitalization items and offering mechanics. NT219 completed a Phase 1 dose-escalation study showing anti-tumor activity in recurrent/metastatic head and neck cancer and an investigator-initiated Phase 2 study with University of Colorado was initiated in June 2025. CM24 is in a randomized open-label Phase 2 study in pancreatic ductal adenocarcinoma in collaboration with Bristol Myers Squibb, with interim data expected in the second half of 2023 and topline by end of 2024. The company completed corporate actions changing ADS ratios and a 1:20 share consolidation in 2019. Financing programs include a Sales Agreement with Jefferies for up to USD 50,000,000 and various warrants and ADS offerings. The filing emphasizes significant risks: operating losses, need for additional capital, reliance on third parties for manufacturing and trials, regulatory uncertainty and IP and geopolitical risks.
Purple Biotech Ltd. (PPBT) is a clinical-stage pharmaceutical company focused on oncology candidates including NT219, CM24 and IM1240. The prospectus supplement outlines ongoing and planned clinical programs, collaborations, capitalization items and offering mechanics. NT219 completed a Phase 1 dose-escalation study showing anti-tumor activity in recurrent/metastatic head and neck cancer and an investigator-initiated Phase 2 study with University of Colorado was initiated in June 2025. CM24 is in a randomized open-label Phase 2 study in pancreatic ductal adenocarcinoma in collaboration with Bristol Myers Squibb, with interim data expected in the second half of 2023 and topline by end of 2024. The company completed corporate actions changing ADS ratios and a 1:20 share consolidation in 2019. Financing programs include a Sales Agreement with Jefferies for up to USD 50,000,000 and various warrants and ADS offerings. The filing emphasizes significant risks: operating losses, need for additional capital, reliance on third parties for manufacturing and trials, regulatory uncertainty and IP and geopolitical risks.